FibroBiologics, Inc. Common Stock
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications. The company was founded in 2021 and is based in Houston, Texas.
FibroBiologics, Inc. Common Stock (FBLG) - Net Assets
Latest net assets as of September 2025: $125.00K USD
Based on the latest financial reports, FibroBiologics, Inc. Common Stock (FBLG) has net assets worth $125.00K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.74 Million) and total liabilities ($8.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $125.00K |
| % of Total Assets | 1.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
FibroBiologics, Inc. Common Stock - Net Assets Trend (2022–2025)
This chart illustrates how FibroBiologics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for FibroBiologics, Inc. Common Stock (2022–2025)
The table below shows the annual net assets of FibroBiologics, Inc. Common Stock from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $2.73 Million | +118.28% |
| 2024-06-30 | $1.25 Million | +131.36% |
| 2023-06-30 | $-4.00 Million | -209.77% |
| 2022-06-30 | $-1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to FibroBiologics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3276700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $38.25 Million | 1398.65% |
| Total Equity | $2.73 Million | 100.00% |
FibroBiologics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of FibroBiologics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Icandy Interactive Ltd
AU:ICI
|
$11.01 Million |
|
Pineapple Financial Inc.
NYSE MKT:PAPL
|
$11.02 Million |
|
Key Energy Services Inc
PINK:KEGX
|
$11.02 Million |
|
Array Inc
TWO:3664
|
$11.03 Million |
|
Wonpoong Corporation
KQ:008370
|
$11.00 Million |
|
S&S Power Switchgears Limited
NSE:S&SPOWER
|
$11.00 Million |
|
Pelangio Exploration Inc
PINK:PGXPF
|
$11.00 Million |
|
Spinnova Oy
HE:SPINN
|
$11.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FibroBiologics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,253,000 to 2,735,000, a change of 1,482,000 (118.3%).
- Net loss of 11,161,000 reduced equity.
- New share issuances of 7,507,000 increased equity.
- Other factors increased equity by 5,136,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.16 Million | -408.08% |
| Share Issuances | $7.51 Million | +274.48% |
| Other Changes | $5.14 Million | +187.79% |
| Total Change | $- | 118.28% |
Book Value vs Market Value Analysis
This analysis compares FibroBiologics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $-0.04 | $0.26 | x |
| 2023-06-30 | $-0.12 | $0.26 | x |
| 2024-06-30 | $0.04 | $0.26 | x |
| 2025-06-30 | $0.08 | $0.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FibroBiologics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -408.08%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 6.01x
- Recent ROE (-408.08%) is above the historical average (-430.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.45 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.72 Million |
| 2024 | -1315.64% | 0.00% | 0.00x | 9.43x | $-16.61 Million |
| 2025 | -408.08% | 0.00% | 0.00x | 6.01x | $-11.43 Million |
Industry Comparison
This section compares FibroBiologics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FibroBiologics, Inc. Common Stock (FBLG) | $125.00K | 0.00% | 68.95x | $11.01 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |